Lipocalin 2 Protein (LCN2) (AA 21-198) (Fc Tag)

Catalog No. ABIN7275321

Product Details

Target: Lipocalin 2 (LCN2)

Protein Type: Recombinant

Protein Characteristics: AA 21-198

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This Lipocalin 2 protein is labelled with Fc Tag.

Purpose: Human NGAL/Lipocalin-2 Protein

Sequence: Gln21-Gly198

Characteristics: Recombinant Human NGAL/Lipocalin-2 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gln21-Gly198.

Purity: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human NGAL, hFc Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-NGAL Antibody, hFc Tag with the EC50 19.1ng/ml determined by ELISA. See testing image for detail.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in 50 mM MES,150 mM NaCl ( pH 6.5).

Buffer: Lyophilized from 0.22μm filtered solution in 50 mM MES,150 mM NaCl ( pH 6.5). Normally 8 % trehalose is added as protectant before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: Lipocalin 2 (LCN2)

Alternative Name: NGAL (LCN2 Products)

Background: Acute kidney injury (AKI) is one of the most common complications of various serious conditions, and early diagnosis is therefore critical for the treatment of AKI. Recent evidence demonstrates that neutrophil gelatinase- associated lipocalin (NGAL) is closely associated with AKI. Several experimental and clinical studies have shown that the expression of urine and serum NGAL increases significantly in AKI. NGAL shows potential to be a new effective early biochemical marker of AKI. Further studies are needed to confirm the significant advantages of NGAL in the diagnosis of early AKI and its value in clinical applications.

Molecular Weight: 47.2 kDa. Due to glycosylation, the protein migrates to 48-52 kDa based on Tris-Bis PAGE result.

Pathways: Cellular Response to Molecule of Bacterial Origin, Transition Metal Ion Homeostasis